CDK4/6抑制剂在晚期乳腺癌中的作用?

IF 3.1 Q2 ONCOLOGY

Oncology Reviews Pub Date : 2019-07-22 DOI:10.4081/oncol.2019.416

Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed

{"title":"CDK4/6抑制剂在晚期乳腺癌中的作用?","authors":"Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed","doi":"10.4081/oncol.2019.416","DOIUrl":null,"url":null,"abstract":"Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.416","citationCount":"8","resultStr":"{\"title\":\"CDK4/6 inhibitors in advanced breast cancer, what is beyond?\",\"authors\":\"Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed\",\"doi\":\"10.4081/oncol.2019.416\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.\",\"PeriodicalId\":19487,\"journal\":{\"name\":\"Oncology Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2019-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/oncol.2019.416\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/oncol.2019.416\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2019.416","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 8

摘要

对激素治疗的抵抗被认为是晚期乳腺癌(ABC)治疗的主要临床挑战。使用CDK4/6抑制剂(CDK4/6I)可能会改变治疗前景。在这篇强制性的综述中，我们将重点关注CDK4/6I在HR+/HER2- ABC治疗中的适用作用、耐药机制以及未来的实施前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.